What is the recommended management of chronic kidney disease‑mineral and bone disorder (CKD‑MBD) in adults with CKD stages 3‑5 (eGFR <60 mL/min/1.73 m²)?

Management of CKD-MBD in Adults with CKD Stages 3-5

In adults with CKD stages 3-5, management of CKD-MBD should be based on serial monitoring of phosphate, calcium, and PTH levels considered together, with treatment focused on progressively or persistently elevated values rather than single abnormal measurements, while avoiding routine use of calcitriol/vitamin D analogs in non-dialysis patients and restricting calcium-based phosphate binders to prevent vascular calcification. 1

Biochemical Monitoring Strategy

Monitoring Frequency

The frequency of laboratory monitoring should escalate with declining kidney function 1:

• CKD Stage 3a-3b (eGFR 30-59): Measure calcium and phosphate every 6-12 months; PTH based on baseline level and CKD progression 1
• CKD Stage 4 (eGFR 15-29): Measure calcium and phosphate every 3-6 months; PTH every 6-12 months 1
• CKD Stage 5 (eGFR <15): Measure calcium and phosphate every 1-3 months; PTH every 3-6 months 1
• Alkaline phosphatase: Annually in stages 4-5, or more frequently if PTH is elevated 1

Treatment Approach Philosophy

Critical principle: Therapeutic interventions targeting one biochemical parameter often adversely affect others, so treatment decisions must be based on serial assessments of all parameters together, not isolated values 1

Phosphate Management

When to Treat

• Do not treat based on a single elevated phosphate value 1
• Initiate treatment only when phosphate is progressively rising or persistently elevated above normal range 1
• Current evidence does not support maintaining normal phosphate levels in non-dialysis CKD patients, and aggressive phosphate-lowering carries safety concerns 1

Treatment Hierarchy

Dietary modification first 1:

• Limit dietary phosphate intake, considering phosphate source (animal, vegetable, or food additives) 1
• Food additives represent "hidden" phosphate sources that warrant particular attention 1

Phosphate binders when needed 1:

• Restrict calcium-based phosphate binders in the presence of arterial calcification, adynamic bone disease, or persistently low PTH 1
• Avoid inappropriate calcium loading across all CKD stages due to harm from hypercalcemia 1
• Choice should account for CKD stage, other CKD-MBD components, concomitant therapies, and side effects 1

Common pitfall: Aggressive phosphate-lowering with calcium-based binders can promote vascular calcification and increase cardiovascular risk 1

Calcium Management

Target Approach

• Adults: Avoid hypercalcemia; do not routinely target "normal" calcium 1
• New evidence demonstrates hypercalcemia is harmful across all CKD stages 1
• Dialysis patients: Use dialysate calcium concentration between 1.25-1.50 mmol/L (2.5-3.0 mEq/L) 1

PTH Management

Non-Dialysis CKD (Stages 3-5)

Evaluation threshold 1:

• The optimal PTH level is unknown 1
• Evaluate patients only when PTH is progressively rising or persistently above the upper normal limit 1
• Do not treat based on a single elevated PTH value 1
• Modest PTH increases may represent appropriate adaptive responses to declining kidney function 1

Initial management steps 1:

1. Evaluate for modifiable factors: hyperphosphatemia, hypocalcemia, high phosphate intake, vitamin D deficiency 1
2. Correct abnormalities with dietary phosphate restriction, phosphate binders, calcium supplements, and/or native vitamin D 1

Pharmacologic therapy 1:

• Do not routinely use calcitriol or vitamin D analogs in non-dialysis CKD 1
• Reserve calcitriol/vitamin D analogs only for CKD stages 4-5 with severe and progressive hyperparathyroidism 1
• Rationale: Increased risk of hypercalcemia without proven patient-level benefits 1

Dialysis Patients (CKD Stage 5D)

PTH target range 1:

• Maintain intact PTH at approximately 2-9 times the upper normal limit 1
• Marked changes in either direction within this range should prompt treatment adjustment 1

Treatment options for PTH-lowering 1:

• Calcimimetics, calcitriol, or vitamin D analogs are all acceptable first-line options (listed alphabetically without preference) 1
• Combination therapy with calcimimetics plus calcitriol or vitamin D analogs is also acceptable 1
• Key controversy: The EVOLVE trial with cinacalcet did not meet its primary endpoint, though secondary analyses suggested potential benefits on patient-level outcomes; no positive mortality data exist for calcitriol or vitamin D analogs either 1
• Choice should be guided by concomitant therapies, patient's calcium and phosphate levels, and dialysate calcium concentration 1

Refractory cases 1:

• Parathyroidectomy for severe hyperparathyroidism failing medical/pharmacological therapy 1

Bone Assessment and Fracture Risk

BMD Testing

Major guideline change from 2009: DXA BMD testing now recommended if results will impact treatment decisions 1

• Multiple prospective studies since 2009 demonstrate that lower DXA BMD predicts fractures in CKD stages 3a-5D 1
• BMD testing is appropriate for patients with evidence of CKD-MBD and/or osteoporosis risk factors 1

Bone Biopsy

• Remains the diagnostic gold standard for distinguishing types of renal osteodystrophy 1
• Reasonable to perform if knowledge of renal osteodystrophy type will impact treatment decisions 1
• Critical point: Facilities lacking bone biopsy capability should not withhold antiresorptive therapy from high-risk fracture patients 1

Osteoporosis Treatment

CKD Stages 1-2 1:

• Manage as general population per WHO criteria 1

CKD Stage 3a-3b with normal PTH 1:

• Treat osteoporosis/high fracture risk as general population 1

CKD Stages 3a-5D with CKD-MBD abnormalities 1:

• Treatment choices must account for magnitude and reversibility of biochemical abnormalities and CKD progression 1
• Consider bone biopsy before antiresorptive therapy 1
• Warning: Antiresorptives exacerbate low bone turnover; denosumab may cause significant hypocalcemia 1

Key Clinical Pitfalls to Avoid

1. Treating single abnormal values: Always base decisions on serial assessments showing progressive or persistent abnormalities 1

2. Aggressive phosphate normalization in non-dialysis CKD: No proven benefit and potential harm 1

3. Excessive calcium loading: Hypercalcemia is harmful; restrict calcium-based binders, especially with arterial calcification 1

4. Routine calcitriol use in non-dialysis CKD: Increases hypercalcemia risk without proven mortality benefit 1

5. Ignoring interconnected parameters: Treating one abnormality (e.g., phosphate) often worsens others (e.g., calcium), requiring holistic assessment 1

6. Withholding fracture treatment: Don't deny antiresorptive therapy to high-risk patients just because bone biopsy is unavailable 1